Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H31Cl2N7O3 |
Molecular Weight | 560.475 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCN(CC1)C2=CC=C(NC3=CC(=NC=N3)N(C)C(=O)NC4=C(Cl)C(OC)=CC(OC)=C4Cl)C=C2
InChI
InChIKey=QADPYRIHXKWUSV-UHFFFAOYSA-N
InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)
DescriptionSources: https://www.pharmacodia.com/yaodu/html/v1/chemicals/d0b9a6a56ca7fd6ebad617bcda8365a6.htmlCurator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/ | DOI: 10.1158/2159-8290.CD-NB2014-057 | http://meetinglibrary.asco.org/content/159420-173
Sources: https://www.pharmacodia.com/yaodu/html/v1/chemicals/d0b9a6a56ca7fd6ebad617bcda8365a6.html
Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/ | DOI: 10.1158/2159-8290.CD-NB2014-057 | http://meetinglibrary.asco.org/content/159420-173
Infigratinib (BGJ398), a potent, orally bioavailable, small-molecule pan-FGFR kinase inhibitor. FGFR genetic alterations are the most significant predictors for BGJ398 sensitivity. It is currently in phase 2 trials for Cholangiocarcinoma, Glioblastoma and Solid tumors. Detected adverse events were hyperphosphatemia, fatigue, constipation, cough and nausea. Other adverse events were generally mild and included stomatitis, hair loss, decreased appetite, and fatigue.
Originator
Sources: https://adisinsight.springer.com/drugs/800031184
Curator's Comment: # Novartis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3650 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21936542 |
0.9 nM [IC50] | ||
Target ID: CHEMBL4142 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21936542 |
1.4 nM [IC50] | ||
Target ID: CHEMBL2742 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21936542 |
1.0 nM [IC50] | ||
Target ID: CHEMBL3973 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21936542 |
60.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02160041
1 x 100 mg and 1 x 25 mg capsules once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21936542
BGJ398 inhibits the proliferation of the FGFR1-, FGFR2-Q, and FGFR3-dependent BaF3 cells with IC50 of 2.9 μM, 2.0 μM and 2 μM, respectively. BGJ398 interferes with autophosphorylation on specific tyrosine residues including FGFR-WT, FGFR2-WT, FGFR3-K650E, FGFR3-S249C and FGFR4-WT with IC50 of 4.6 nM, 4.9 nM, 5 nM, 5 nM and 168 nM, respectively. BGJ398 suppresses proliferation of the cancer cells with wild-type (WT) FGFR3 overexpression such as RT112, RT4, SW780 and JMSU1 with IC50 of 5 nM, 30 nM, 32 nM and 15 nM, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1742
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
||
|
FDA ORPHAN DRUG |
833221
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
||
|
FDA ORPHAN DRUG |
707019
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
||
|
NCI_THESAURUS |
C1967
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
A4055ME1VK
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY | |||
|
CHEMBL1852688
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY | |||
|
53235510
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY | |||
|
10032
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY | |||
|
DB11886
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY | |||
|
2550729
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY | |||
|
GH-50
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY | |||
|
63451
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY | |||
|
DTXSID70236238
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY | |||
|
Infigratinib
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY | |||
|
C88302
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY | |||
|
A4055ME1VK
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY | |||
|
872511-34-7
Created by
admin on Sat Dec 17 21:13:11 UTC 2022 , Edited by admin on Sat Dec 17 21:13:11 UTC 2022
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)